10 results match your criteria: "Lucerne and University of Bern[Affiliation]"
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study.
Cancer
December 2024
Unisanté, Center for Primary Care and Public Health, Department of Epidemiology and Health Systems, University of Lausanne, Lausanne, Switzerland.
Background: Patient experience surveys gather information on various aspects of care via numerous survey items. Identifying the most critical areas of patient experience to prioritize for quality care improvement can be challenging. The objective of this study was to determine which care experience items are the drivers influencing patients' overall rating of cancer care.
View Article and Find Full Text PDFProteomic profiling for biomarker discovery in heparin-induced thrombocytopenia.
Blood Adv
June 2024
Department of Clinical Chemistry, Inselspital University Hospital Bern, Bern, Switzerland.
Article Synopsis
- New analytical techniques allow for the simultaneous assessment of hundreds of proteins, helping to understand their roles in diseases like heparin-induced thrombocytopenia (HIT).
- Researchers used four panels of the Olink proximity extension assay on patients suspected of HIT to identify potential new biomarkers related to thrombus formation, inflammation, and the immune response.
- The study indicated that soluble P-selectin could serve as a significant marker for HIT, with future research planned to evaluate its diagnostic and prognostic value in patient care.
Accuracy of Diagnosing Heparin-Induced Thrombocytopenia.
JAMA Netw Open
March 2024
Department of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
Importance: Heparin-induced thrombocytopenia (HIT) is a life-threatening condition that requires urgent diagnostic clarification. However, knowledge of the diagnostic utility of the recommended diagnostic tests is limited in clinical practice.
Objective: To evaluate the current diagnostic practice for managing the suspicion of HIT.
Immunothrombosis and Complement Activation Contribute to Disease Severity and Adverse Outcome in COVID-19.
J Innate Immun
December 2023
Department of Hematology, Kantonsspital Luzern, Lucerne and University of Bern, Bern, Switzerland.
Severe COVID-19 is characterized by systemic inflammation and multiple organ dysfunction syndrome (MODS). Arterial and venous thrombosis are involved in the pathogenesis of MODS and fatality in COVID-19. There is evidence that complement and neutrophil activation in the form of neutrophil extracellular traps are main drivers for development of microvascular complications in COVID-19.
View Article and Find Full Text PDFSwiss Survey on current practices and opinions on clinical constellations triggering the search for PNH clones.
Front Med (Lausanne)
July 2023
Department of Hematology, Kantonsspital Luzern, Lucerne and University of Bern, Bern, Switzerland.
Unlabelled: This national survey investigated the current practice in Switzerland by collecting participants' opinions on paroxysmal nocturnal hemoglobinuria (PNH) clone assessment and clinical practice.
Aim: This study aimed to investigate clinical indications prompting PNH clones' assessment and physician's accessibility of a flow cytometry facility, and also to understand clinical attitudes on the follow-up (FU) of patients with PNH clones.
Methods: The survey includes 16 multiple-choice questions related to PNH and targets physicians with a definite level of experience in the topic using two screener questions.
A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: A prospective, multicenter, observational study.
EClinicalMedicine
January 2023
Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Article Synopsis
- Diagnosing heparin-induced thrombocytopenia (HIT) is difficult at the bedside, leading to potential delays in diagnosis or overtreatment, and researchers aimed to improve this using machine-learning algorithms.
- A study with 1393 patients from multiple centers found high accuracy in diagnosing HIT using a machine-learning tool that considered various clinical and lab factors, outperforming the current methods.
- The machine-learning models significantly reduced false-negative and false-positive rates compared to the existing diagnostic algorithm, demonstrating their potential for better clinical outcomes in HIT diagnosis.
Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study.
Front Cardiovasc Med
March 2022
Department of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Background: Applying a single anti-Xa assay, calibrated to unfractionated heparin to measure rivaroxaban, apixaban, and edoxaban would simplify laboratory procedures and save healthcare costs.
Aim: We hypothesized that a heparin-calibrated anti-Xa assay would accurately measure rivaroxaban, apixaban, and edoxaban drug concentrations and correctly predict clinically relevant drug levels.
Methods: This analysis is part of the Simple-Xa study, a prospective multicenter cross-sectional study conducted in clinical practice.
Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements.
Front Cardiovasc Med
September 2021
Department of Clinical Chemistry, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
The thrombin generation assay (TG) is a promising approach to measure the degree of anticoagulation in patients treated with direct oral anticoagulants (DOAC). A strong association with plasma drug concentrations would be a meaningful argument for the potential use to monitor DOAC. We aimed to study the correlation of TG with rivaroxaban, apixaban, and edoxaban drug concentrations in a large, prospective multicenter cross-sectional study.
View Article and Find Full Text PDFRecommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland.
Swiss Med Wkly
April 2020
Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne and University of Bern, Switzerland.
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that occurs in 0.1–5% of heparin treated patients. Management of acute HIT currently involves (1) cessation of heparin exposure, and (2) inhibition of coagulation with an anticoagulant other than heparin.
View Article and Find Full Text PDFLong-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
BMC Cancer
September 2019
Breast Center St. Gallen, Kantonsspital, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
Background: The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 22/99 trial was to characterize the specific subset of patients deriving long-term benefit from trastuzumab monotherapy alone and to identify potential predictive factors of long-term response.
Methods: This is an unplanned post-hoc analysis of patients randomized to Arm A (trastuzumab monotherapy).